HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment
- Conditions
- Covid19
- Interventions
- Other: Baseline blood sampleOther: Baseline and during hospitalization blood samples
- Registration Number
- NCT04613297
- Lead Sponsor
- Hopital Foch
- Brief Summary
The aim of the research is to study the immune checkpoint linked to the HLA-G molecule in the dysregulation of the control of COVID-19 infection.
- Detailed Description
Single-center, prospective, open-ended, interventional study with minimal risks and constraints. Patients will be divided into 3 groups: patients not infected with COVID-19, patients infected with COVID-19 not hospitalized, patients infected with COVID-19 hospitalized.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 91
- Patient with possible or confirmed infection by COVID-19
- Patient without liberty or guardianship
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description COVID-19 uninfected patients Baseline blood sample Patient with negative PCR result non-hospitalized COVID-19 infected patients Baseline blood sample Patient with positive PCR result who does not require hospitalization for COVID-19 hospitalized COVID-19 infected patients Baseline and during hospitalization blood samples Patient with positive PCR who require hospitalization for COVID-19
- Primary Outcome Measures
Name Time Method Comparison of the percentage of T cells expressing the HLA-G receptor ILT2 (CD3+CD4+ILT2+ T cells, and CD3+CD8+ILT2+ T cells) between the 3 groups of patients. 1 month The CD3 + T lymphocyte cell populations (CD4 + ILT2 + and CD8 + ILT2 +) will be compared between the groups of patients
Comparison of the expression of circulating soluble HLA-G, between the groups of patients. 1 day Blood levels of soluble HLA-G and plasma microvesicles with expression of HLA-G will be compared between the groups of patients.
- Secondary Outcome Measures
Name Time Method 1 month survival 1 month Vital status collected 1 month post inclusion for all the patients
Comparison of the expression of one of the cell receptors of the SARS-CoV-2 virus, called BSG (Basigin), whose expression is modified by the interaction between HLA-G. 1 day The expression of the BSG cell receptor induced by HLA-G will be compared between COVID19 patients and uninfected patients.
Assessment of the severity of the disease according to the isoform of HLA-G 1 month Comparison of the isoforms (alleles) of HLA-G regarding the severity of the disease for the infected patients.
Trial Locations
- Locations (1)
Foch hospital
🇫🇷Suresnes, France